Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4859-

  Maxwell, Jill A ^a   Johnson, Stewart P ^a   McLendon, Roger E ^a   Lister, David W ^a   Horne, Krystle S ^a   Rasheed, Ahmed ^a   Quinn, Jennifer A ^a   Ali Osman, Francis ^a   Friedman, Allan H ^a   Modrich, Paul L ^a   Bigner, Darell D ^a   Friedman, Henry S ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLGUANINE DNA ALKYLTRANSFERASE; DEOXYRIBONUCLEOPROTEIN; PROTEIN MSH6; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DNA REPAIR; FEMALE; GENE MUTATION; GENETIC DISORDER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISMATCH REPAIR DEFICIENCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; ADULT; AGED; BASE MISPAIRING; BRAIN TUMOR; DRUG RESISTANCE; GENETICS; GLIOMA; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; BRAIN NEOPLASMS; DACARBAZINE; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 51049123410     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4807     Document Type: Article

References (52)

1. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005;11:6767-71.
2. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
3. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A1993;90:6424-8.
4. Sibghat U, Day RS III. Incision at O6-methylguanine: thymine mispairs in DNA by extracts of human cells. Biochemistry 1992;31:7998-8008.
5. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-87.
6. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O (6) -benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-83.
7. Wedge SR, Porteous JK, Newlands ES. 3-Aminobenzamide and/or 06-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and 06-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996;74:1030-6.
8. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997; 57:2933-6.
9. Cahill DP Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13: 2038-45.
10. Hunter C, Smith R, Cahill DP et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006;66:3987-91.
11. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16: 3851-7.
12. McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 1998; 78:643-4.
13. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-11.
14. Xicola RM, Llor X, Pons E, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 2007;99:244-52.
15. Oda S, Oki E, Maehara Y, Sugimachi K. Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res 1997;25:3415-20.
16. Drummond JT, Genschel J, Wolf E, Modrich P. DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSα/hMutSβ ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci U S A1997;94:10144-9.
17. Maxwell JA, Johnson SP, Quinn JA, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 2006;5: 2531-9.
18. Umar A, Risinger JI, Glaab WE, Tindall KR, Barrett JC, Kunkel TA. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 1998;148: 1637-46.
19. Parc YR, Hailing KC, Wang L, et al. HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res 2000;60:2225-31.
20. Warren JJ, Pohlhaus TJ, Changela A, Iyer RR, Modrich PL, Beese LS. Structure of the human Mut Sα DNA lesion recognition complex. Mol Cell 2007;26: 579-92.
21. Dayhoff MO, Schwartz RM, Orcutt BC. A model of evolutionary change in proteins. Atlas of protein sequence and structure. Natl Biomed Res Found (Washington DC) 1978;5:345-52.
22. Holler M, Westin G, Jiricny J, Schaffner W. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev 1988;2:1127-35.
23. Szadkowski M, Jiricny J. Identification and functional characterization of the promoter region of the human MSH6 gene. Genes Chromosomes Cancer 2002;33:36-46.
24. Gazzoli I, Kolodner RD. Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms. Mol Cell Biol 2003;23:7992-8007.
25. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive lowgrade glioma. J Clin Oncol 2003;21:646-51.
26. Yung WK, Prados MD, Yaya-Tur R, et al. Temodal Brain Tumor Group. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-71.
27. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999;11:162-7.
28. Bacolod MD, Johnson SP, Ali-Osman F, et al. Mechanisms of resistance to 1,3-bis(2-chloroethyl)- 1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 2002;1:727-36.
29. Bacolod MD, Johnson SP, Pegg AE, et al. Brain tumor cell lines resistant to O6-benzylguanine/1,3- bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 2004;3:1127-35.
30. Friedman HS, Pegg AE, Johnson SP, et al. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother Pharmacol 1999;43:80-5.
31. He XM, Ostrowski LE, von Wronski MA, et al. Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines. Cancer Res 1992;52:1144-8.
32. Ostrowski LE, von Wronski MA, Bigner SH, et al. Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. Carcinogenesis 1991;12:1739-44.
33. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29.
34. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56:783-8.
35. Mineura K, Watanabe K, Yanagisawa T, Kowada M. Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors. Biochim Biophys Acta 1996;1289:105-9.
36. Silber JR, Mueller BA, Ewers TG, Berger MS. Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 1993;53:3416-20.
37. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A1990;87:5368-72.
38. Domoradzki J, Pegg AE, Dolan ME, Maher VM, McCormick JJ. Depletion of 06-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 1985;6:1823-6.
39. Qian XC, Brent TP. Methylation hot spots in the 5′ flanking region denote silencing of the 06-methylguanine-DNA methyltransferase gene. Cancer Res 1997;57:3672-7.
40. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J, Karran P. Epigenetic regulation of the MGMTand hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 2000;60: 3262-70.
41. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004:10:1871-4.
42. Dams E. Van de Kelft EJ, Martin JJ, Verlooy J, Willems PJ. Instability of microsatellites in human gliomas. Cancer Res1995;55:1547-9.
43. Lundin DA, Blank A, Berger MS, Silber JR. Microsatellite instability is infrequent in sporadic adult gliomas. Oncol Res 1998:10:421-8.
44. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, Schackert G. Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:87-93.
45. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R. Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 2003;22:180-6.
46. Papadopoulos N, Nicolaides NC, Liu B, et al. Mutations of GTBP in genetically unstable cells. Science 1995;268:1915-7.
47. Lettieri T, Marra G, Aquilina G, et al. Effect of hMSH6 cDNA expression on the phenotype of mismatch repair-deficient colon cancer cell line HCT15. Carcinogenesis 1999;20:373-82.
48. Marsischky GT, Filosi N. Kane MF, Kolodner R. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev1996;10:407-20.
49. Ercoli A, Ferrandina G, Genuardi M, et al. Microsatellite instability is not related to response to cisplatinbased chemotherapy in cervical cancer. Int J Gynecol Cancer 2005;15:308-11.
50. Boland CR. Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58 5248-57
51. Bacani J, Zwingerman R. Di Nicola N, et al Tumor microsatellite instability in early onset gastric cancer J Mol Diagn 2005;7:465. 77
52. Wong YF, Cheung TH. Lo KW, et al Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers Carcr nogenesis 2006;27:951-5